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Radiotherapy is an important modality used in the treatment of more than 50% of cancer
patients in the US. However, despite sophisticated techniques for radiation delivery as well
as the combination of radiation with chemotherapy, tumors can recur. Thus, any method
of improving the local control of the primary tumor by radiotherapy would produce a major
improvement in the curability of cancer patients. One of the challenges in the field is
to understand how the tumor vasculature can regrow after radiation in order to support
tumor recurrence, as it is unlikely that any of the endothelial cells within the tumor could
survive the doses given in a typical radiotherapy regimen. There is now considerable
evidence from both preclinical and clinical studies that the tumor vasculature can be
restored following radiotherapy from an influx of circulating cells consisting primarily of
bone marrow derived monocytes and macrophages. The radiation-induced influx of bone
marrow derived cells (BMDCs) into tumors can be prevented through the blockade of
various cytokine pathways and such strategies can inhibit tumor recurrence. However,
the post-radiation interactions between surviving tumor cells, recruited immune cells,
and the remaining stroma remain poorly defined. While prior studies have described the
monocyte/macrophage inflammatory response within normal tissues and in the tumor
microenvironment, less is known about this response with respect to a tumor after
radiation therapy. The goal of this review is to summarize existing research studies to
provide an understanding of how the myelomonocytic lineage may influence vascular
recovery within the irradiated tumor microenvironment.
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TUMOR-ASSOCIATEDMACROPHAGES
Infiltrating leukocytes are a common finding in solid tumors,
first described by Virchow in 1863 and confirmed in modern
studies (Wood and Gollahon, 1977; Milas et al., 1987; Balkwill
and Mantovani, 2001). Tumor-associated macrophages (TAMs)
are recruited to tumors and can promote tumor growth, sur-
vival, and may result in resistance to therapeutic treatments
(De Palma and Lewis, 2013). As tumors mature, they acquire a
heterogeneous, infiltrative population of bone marrow-derived
cells (BMDCs), including a diverse array of myelomonocytic
cells: neutrophils, dendritic cells, myeloid derived suppressor cells
and monocytes/macrophages (Akashi et al., 2000; Nagaraj and
Gabrilovich, 2010). The extent of TAM infiltration appears to cor-
relate with a poor clinical prognosis and an increase in tumor
burden (Takanami et al., 1999; Shieh et al., 2009; Toge et al., 2009).
TAMs originate as circulating monocytes recruited to tumors
by cytokine gradients produced by tumor cells as well as the
tumor stroma (Mantovani et al., 1992). A diverse array of
cytokines and growth factors has been demonstrated to stimu-
late macrophage recruitment to tumors (Balkwill, 2004; Allavena
et al., 2008). Initially, TAMs were felt to have anti-tumor proper-
ties; however, Mantovani et al. found that isolated macrophages
from a weakly immunogenic sarcoma cell line were able to stim-
ulate tumor cell growth in vitro (Mantovani, 1978). TAMs have
now been found by many investigators to also promote tumor
growth in vivo, often by producing a proangiogenic environment
(Folkman, 1974; Polverini et al., 1977; Lin and Pollard, 2004).
As a simplified paradigm, macrophages are frequently consid-
ered to be polarized toward two specific phenotypes; however, it
is important to realize there are many macrophage phenotypes
with different specialized functions (Qian and Pollard, 2010).
Classically activated macrophages (M1) are “pro-inflammatory”
cells designed to protect the host from pathogenic infections.
M1 macrophages are stimulated by LPS and IFN-gamma to pro-
duce IL-12, IL-6, inducible NO synthase (iNOS), and TNF-alpha
(Modolell et al., 1995). These M1 populations have an enhanced
ability to generate reactive oxygen species, upregulate phago-
cytosis, and have enhanced functionality as antigen presenting
cells (Martinez et al., 2009). In contrast, M2 macrophages (alter-
natively activated) are considered “anti-inflammatory” as they
promote tissue repair through IL-4, IL-13 and prostaglandin
signaling and result in the production of IL-10 and TGF-beta
(Corraliza et al., 1995; Mantovani et al., 2009). M2 populations
are able to suppress cytokine production and reduce activation of
T-cells, decrease antigen presenting ability, promote angiogenesis,
stimulate extracellular matrix degradation, and enhance cell sur-
vival (Murdoch et al., 2008; Lu et al., 2011). Increased arginase I
(Arg I) expression is often used as a marker of the M2 phenotype
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due to changes in arginine metabolism away from NO generation
to polyamine production (Ho and Sly, 2009). Many studies have
found that the tumor microenvironment preferentially polarizes
TAMs to theM2 phenotype (Gabrilovich et al., 2012; Ruffell et al.,
2012).
The activation or polarization toward a particular macrophage
phenotype appears to be dependent on the cytokine milieu, the
presence of specific growth factors, and the level of hypoxia
within the tumor microenvironment (Munder et al., 1998;
Goerdt et al., 1999; Gordon, 2003; Mosser, 2003; Stout et al.,
2005). However, it should be noted that macrophages can also
simultaneously produce M1 as well as M2-related cytokines
and that the expression is highly dependent on the tumor
type, stage, and location as well as the host microenviron-
ment. Additionally, the dynamic tumor environment may con-
stantly shift the ratio of macrophage phenotypes depending on
the current environmental conditions (Murdoch et al., 2004;
Pollard, 2004). For example, an unregulated M1 population could
result in a shift toward a chronic inflammatory state, while an
uncontrolled M2 population could result in severe immuno-
suppression (Mantovani et al., 2004; Condeelis and Pollard,
2006). Furthermore, lack of M1 signals (i.e., downregulated
tumor/stromal production of IL-4, IL-10, and IL-13) drive TAMs
toward the M2 phenotype (Mantovani et al., 2004; Pollard, 2004;
Solinas et al., 2009).
In summary, TAMs are bone marrow derived monocytic cells
with unique functional subsets that are recruited to tumors
by cytokine gradients and frequently differentiate into the
M2 macrophage phenotype. TAM infiltration can result in an
immunosuppressed environment, the promotion of proangio-
genic pathways, and consequently, enhanced tumor growth and
tumor cell survival.
HYPOXIA AND THE PROANGIOGENIC ROLE OF TAMs
The tumor microenvironment is often transiently or chronically
in a state of low oxygen tension (Vaupel andMayer, 2007). To sur-
vive in a hypoxic environment, tumorsmust establish a functional
vascular network (See Figure 1). Tumors frequently adapt to
hypoxia by preventing the degradation of hypoxia-induced tran-
scription factor complexes (i.e., HIF1 and HIF2) resulting in their
stabilization and subsequent transcription of genes that promote
tumor survival, including proangiogenic cytokines (Giaccia et al.,
2004; Keith et al., 2012). Using primary human macrophages,
Fang et al. demonstrated that HIF1 and HIF2 co-regulate many
hypoxia-related genes; however, by using siRNA specific knock-
down studies of HIF1 and HIF2, they found that each of these
genes can target certain hypoxia-associated genes independently
(Fang et al., 2009).
TAMs commonly associate in necrotic, low oxygenated areas of
tumors (Leek et al., 1996; Burke et al., 2003; Lewis and Murdoch,
FIGURE 1 | Representation ofthe microenvironment of pre- and
postirradiated tumors. The post-irradiated tumor has increased levels of
hypoxia, upregulated HIF 1/2 signaling, and expression of a diverse spectrum
of cytokines as well as a greater recruitment and influx of bone marrow
derived TAMs. TEMs commonly associate with the vasculature, while
CD68+ TAMs frequently localize to areas of severe hypoxia.
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2005). Hypoxic environments increase expression of the CXCR4
receptor on TAMs and increase the chemotactic response to its
ligand, stromal cell-derived factor-1 (SDF-1/CXCL-12) (Schioppa
et al., 2003). Localization of TAMs to hypoxic regions is mediated
by cytokine gradients resulting from hypoxia-inducedHIF1/2 sta-
bilization (Talks et al., 2000; Murdoch et al., 2004; Jin et al.,
2006; Knowles and Harris, 2007; Han et al., 2008). Cramer et al.
demonstrated that HIF1 expression was required for myeloid cell
motility and invasiveness (Cramer et al., 2003). Furthermore, Du
et al. demonstrated that intracranial implants of HIF1-deficient
glioma cells had reduced levels of infiltrating monocytes within
tumors as well as reduced levels of tumor SDF-1 and MMP-9
protein expression (Du et al., 2008).
Modulation of HIF1/2 has been demonstrated to affect
macrophage phenotype as well as function. However, Werno
et al. demonstrated, using a macrophage lineage HIF1 knock-
out model, that TAM infiltration of tumors was not dependent
on HIF1, but HIF1 was necessary to promote the polariza-
tion of TAMs to the M2 phenotype (Werno et al., 2010).
Consistent with this, Doedens and colleagues showed that
whereas hypoxia suppressed T-cell activation within tumors
and resulted in tumor progression, T-cell suppression was
reduced in a HIF1 macrophage lineage specific knockout
model and resulted in decreased tumor growth (Doedens
et al., 2010). Both HIF1 and HIF2 appear to be impor-
tant regulators of the M1 and M2 polarization phenotypes.
Takeda et al. reported that classical activation cytokines (IFN-
gamma, LPS) increased HIF1 mRNA, but strongly repressed
HIF2 mRNA production, and, conversely, IL-4, the alternative
activation cytokine, resulted in an increase of HIF2 mRNA
(Takeda et al., 2010). Furthermore, M2-polarized macrophages
demonstrated an upregulation of HIF2 mRNA. HIF2 was also
found to regulate Arg I protein expression; however, in con-
trast, HIF1 stabilization increased iNOS expression. Deletion of
HIF2 in mouse macrophages resulted in the inability to gener-
ate an appropriate inflammatory response and murine tumors
implanted in the HIF2 depleted macrophage mouse model
demonstrated decreased TAM infiltration as well as decreased lev-
els of the CSFR1 and CXCR4 receptors (Imtiyaz et al., 2010).
Hypoxia-induced HIF1/2 activation and the resulting differen-
tial effects on TAMs remains a complicated, highly regulated
system playing a significant role in tumor progression and sur-
vival.
With respect to angiogenesis, increased macrophage infiltra-
tion in tumors is associated with a higher vascular density in
breast, glioma, bladder, and esophageal tumors (Leek et al., 1996;
Nishie et al., 1999; Hanada et al., 2000; Koide et al., 2004). TAMs
promote tumor angiogenesis and vascularization by releasing
proangiogenic cytokines such as VEGF and the matrix metal-
loproteinases (Lewis and Pollard, 2006). A study using breast
tumor spheroids found increased VEGF levels and increased
vascular connections when incubated with a macrophage pop-
ulation (Bingle et al., 2006). Similarly, Lewis et al. found that
VEGF mRNA was upregulated in macrophages associated with
human breast cancer (Lewis et al., 2000). Inhibition of VEGF
and VEGFR2 by monoclonal antibodies decreased macrophage
infiltration of in vivo pancreatic tumors (Dineen et al., 2008).
Interestingly, Stockmann et al. used a VEGF-A macrophage spe-
cific lineage knockout in the MMTV-PyMT breast cancer model
and demonstrated similar levels of tumor-associated macrophage
infiltration, decreased tumor VEGFR2 activation, and a decrease
in the length of tumor blood vessels; however, overall tumor
growth was actually enhanced (Stockmann et al., 2008). These
results indicate differential effects of tumor-produced VEGF-A
compared to macrophage-produced VEGF-A on the vascular
network. Further experiments demonstrated that tumor cell
death was enhanced by chemotherapy in tumor-bearing mice
lacking myeloid-specific VEGF-A, suggesting that targeting the
proangiogenic function of TAMs could sensitize tumors to cyto-
toxic therapy. Further interplay of macrophages and endothelial
cells was recently demonstrated by He et al. who demonstrated
that BM-derived hematopoietic cells incubated in vitro with
immortalized endothelial cell layers resulted in the generation
of M2-like macrophage colonies (He et al., 2012). Modulation
of the extracellular matrix also impacts the development of
vascular networks. Coussens et al. demonstrated upregulated
matrix metalloproteinase-9 (MMP-9) production by bone mar-
row derived TAMs and increased tumor angiogenesis (Coussens
et al., 2000). In a related study, Hao et al. found that BMDCs
were recruited to areas of high VEGF expression, expressed ele-
vated levels ofMMP-9, and that capillary development was greatly
reduced in MMP-9 knockout mice (Hao et al., 2008). Thus, the
activation of macrophages within a hypoxic environment results
in the release of proangiogenic cytokines and extracellular matrix
modulating factors.
A subpopulation of tumor-associated macrophages/
monocytes has been identified that express the Tie2 angiopoietin
receptor and are defined as Tie2-expressing monocytes (TEMs)
(De Palma et al., 2005). De Palma et al. using a suicide gene
strategy showed that the selective killing of TEMs, prevented
angiogenesis, and slowed tumor growth in mouse xenografts
(De Palma et al., 2003). Importantly, TEM elimination did not
significantly reduce the overall number of TAMs, indicating that
TEMs are a small subpopulation of macrophages/monocytes.
Venneri et al. demonstrated that a TEM population was present
in human cancers and that these cells were responsive in vitro to
chemotactic migratory stimulation by Ang2, the ligand for the
Tie2 receptor (Venneri et al., 2007). Furthermore, co-injection
studies of TEMs with human glioma cells resulted in more
vascularized tumor xenografts in contrast to co-injection with
TEM-depleted monocyte populations. Of note, TEMs associated
with tumors were found to express the Tie2 receptor at elevated
levels over those of circulating TEMs. Finally, tumor overexpres-
sion of Ang2, resulted in increased accumulation of TEMs within
the tumor microenvironment (Coffelt et al., 2010). Hypoxia
was also demonstrated to upregulate Tie2 expression in TEMs
and downregulate TNF-alpha and IL-12 levels, known anti-
angiogenic cytokines (Murdoch et al., 2007). Hypoxia induced by
vascular disrupting agents produced an increase in tumor SDF-1
expression as well as increased infiltration of CXCR4+ TEMs
(Welford et al., 2011). While TAMs infiltrate the hypoxic and
necrotic regions of tumors, TEMs are more frequently localized
around tumor blood vessels, possess greater proangiogenic
qualities, and can function as an immunosuppressive cell, similar
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to the M2 macrophage phenotype (De Palma et al., 2005; Pucci
et al., 2009; Coffelt et al., 2011).
In addition to the Tie2 population, other proangiogenic
TAM subsets within tumors have been identified including:
CD11b+VEGFR1+ hematopoietic cells and CD11c+MCH-II+
dendritic cell precursors (Hattori et al., 2002; Yang et al., 2004;
De Palma and Naldini, 2006). Similarly, CD11b+Gr-1+ myeloid
cells were also found to mediate resistance to anti-VEGF thera-
pies (Shojaei et al., 2007); however, this population may be related
more toward neutrophils rather than macrophages (Shojaei and
Ferrara, 2008). Movadehi et al. found that MHC IIhi and MHC
IIlow subsets of TAMs were associated with M1 and M2 pheno-
types, respectively (Movahedi et al., 2010). Furthermore, using
the chorioallantoic membrane (CAM) assay of angiogenesis,
MHC IIlow TAMs had a two-fold higher vessel count compared
to MHC IIhi TAMs, demonstrating the enhanced proangiogenic
ability of MHC IIlow TAMs.
TAMs are comprised of several distinct subpopulations and
are recruited to hypoxic regions of tumors via cytokine signal-
ing gradients. In turn, they secrete growth factors to promote
blood vessel formation and proteinases that remodel the tumor
vascular network. Restoration of the vascular supply can result in
tumor survival, proliferation, and potentially, an increased risk of
metastasis.
INTRINSIC RADIATION RESPONSE OF
MONOCYTES/MACROPHAGES
While previous studies found that stimulated mono-
cytes/macrophages are innately resistant to radiotherapy, as
they were demonstrated to be post-mitotic cells, Jenkins et al.
reported that the activation of M2-polarized macrophages
resulted in a higher cell proliferation (Hildebrandt et al., 1998;
Jenkins et al., 2011). This result suggests that within the acute
response to ionizing radiation, M2 macrophages may actually be
more sensitive to radiation-induced DNA damage and result in
cell death, in contrast to quiescent M1-polarized macrophages.
In addition to the intrinsic radiosensitivity of particular M1
or M2 TAM subsets, the influence of ionizing radiation on
macrophage function may be an even more important factor in
tumor survival. Early in vitro research found that radiation inter-
feres with the recognition and degradation of antigens and results
in the failure of macrophages to generate antibody responses
against these targets (Donaldson et al., 1956; Nelson and Becker,
1959; Pribnow and Silverman, 1967). Similarly, Geiger et al.
reported that macrophages of irradiated mice were unable to
stimulate antibody production against Shigella, however, the
phagocytic activity of irradiated macrophages was not impaired
(Geiger and Gallily, 1974). In contrast, Lambert et al. demon-
strated that in vitro radiation resulted in the priming of the
macrophage cell line RAW 264.7 and upregulated MHC Class I
molecules (Lambert and Paulnock, 1987). Additionally, radiation
was found to augment antibody-dependent cell-mediated cyto-
toxicity (ADCC) in the murine macrophage cell line J774 (Duerst
andWerberig, 1991). Other studies have also confirmed that radi-
ation induces the activation of macrophages in vitro and in vivo
through increased rates of phagocytosis, lysosomal enzyme pro-
duction, and H2O2 production as well as the retained capacity to
respond to cytokines (Sablonniere et al., 1983; Gallin et al., 1985;
Gallin and Green, 1987; Hester and Coggin, 1989). Thus, while
the antigen-presenting functions of macrophages are disrupted by
radiation, their innate phagocytic function remains intact.
With respect to cytokine production, radiation-exposed
macrophages have increased IL-1beta mRNA expression, upreg-
ulated TNF-alpha production, are able to potentiate nitric oxide
production by interferon-gamma, and release a variety of growth
factors (i.e., PDGF, IGF-1) (Sherman et al., 1991; O’Brien-Ladner
et al., 1993; Iwamoto and McBride, 1994; Nemoto et al., 1995;
Thornton et al., 1996; Vodovotz et al., 1999; McKinney et al.,
2000). Therefore, the modulation of cytokine production by ion-
izing radiation may influence the macrophage polarization phe-
notype and function. Coates et al. found that macrophages from
irradiated C57BL/6 mice demonstrated enhanced M2 activity
while irradiated macrophages from CBA/CaJ mice had increased
M1 activity (Coates et al., 2008). This result suggested that ion-
izing radiation can induce a phenotypic polarization shift, but
overall, macrophage polarization is dependent on the background
genetic environment.
The above studies demonstrate that ionizing radiation directly
affects macrophage function. The understanding of the intrinsic
radiation response of macrophages, including disrupted anti-
gen recognition, modulation of macrophage polarization to an
immunosuppressive phenotype, and the production of proan-
giogenic cytokines may result in the identification of signaling
pathways that could be targeted to generate a more radiosensi-
tive subpopulation of macrophages, and ultimately, an increase in
tumor responsiveness to radiation therapy.
TAMS AND THE IRRADIATED MICROENVIRONMENT
Radiosensitivity describes the in vitro response of cells to ioniz-
ing radiation, a property that depends critically on the ability of
the cells to repair DNA as well as the activation of other intrinsic
survival pathways. The radioresponse of tumors is defined as the
in vivo change in tumor size after radiation therapy. Several com-
ponents of the tumor microenvironment that can greatly affect
the radioresponse of tumors are: the level of tissue oxygenation,
the sensitivity of tumor endothelial cells to radiation, activation
of tumor stroma to express survival factors, and immune cell
infiltration of the tumor.
An influential study from the joint laboratories of Fuks and
Kolesnick proposed that the radiation sensitivity of tumors to
dose fractions of 10 Gy or more was governed by the sensitiv-
ity of tumor endothelial cells to apoptosis (Garcia-Barros et al.,
2003). However, earlier data from the Suit laboratory had shown
that the radiation dose to control 50% of transplanted tumors
in mice did not depend on the radiation sensitivity of the tumor
stroma (Budach et al., 1993). This apparent contradiction can be
explained by the different assays of tumor response used—growth
delay in the Fuks/Kolesnick study and tumor control (TCD50) by
the Suit lab. Indeed, the dual contribution of tumor cell radiosen-
sitivity and stromal sensitivities was demonstrated by Gerweck
et al. using the growth delay assay (Ogawa et al., 2007). Several
additional reports have also demonstrated that radiation results
in the reduction of blood vessel density (Song et al., 1974; Timke
et al., 2008; Zeng et al., 2008; Kioi et al., 2010).
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In addition to the intrinsic sensitivity of the tumor cells at
the time of irradiation, the effects on the tumor stroma can also
produce events that regulate tumor radioresponse. For example,
the destruction of the vasculature by ionizing radiation causes
hypoxic conditions which results in the activation of HIF-1, stim-
ulation of cytokine signaling cascades, and the recruitment of
macrophages and immune cells (Moeller et al., 2004; Li et al.,
2007; Kioi et al., 2010). This can also occur in normal tissues
as well: alveolar macrophages in the selectively irradiated mouse
lung were shown to increase at 8 weeks post-treatment indicat-
ing the local organ repopulation of macrophages through tissue
resident precursors or from bone marrow progenitor cells (Gross,
1977; Peel and Coggle, 1980). Similarly, Johnston et al. found that
after 15Gy of thoracic radiation, macrophages and lymphocytes
were elevated within irradiated normal tissues at 16 and 24 weeks
post-treatment (Johnston et al., 2004).
Milas et al. found that the tumor-associated macrophage con-
tent varied widely between in vivo tumor implants, but there was
a trend toward increased macrophage content and reduced local
tumor radiocurability (Milas et al., 1987). A second study con-
firmed that a high macrophage content in tumors was able to
overcome the growth delay seen in pre-irradiated tumor beds
implying the importance to TAMs for tumor angiogenesis (Milas,
1990). Similar studies have also demonstrated tumor infiltra-
tion of BMDCs after treatment with ionizing radiation (Stephens
et al., 1978; Jung et al., 1990; Chen et al., 2009). Using a prostate
cancer cell line in mouse xenografts, Tsai et al. demonstrated that
radiation-induced TAM accumulation occurred 1–2 weeks after
treatment and that irradiated TAMs expressed elevated Arg I lev-
els suggesting an M2 phenotype (Tsai et al., 2007). Additionally,
when irradiated TAMs were co-injected with tumor cells, the
resulting tumors demonstrated enhanced growth rates compared
to samples co-injected with unirradiated TAMs. With respect
to the clinical setting, Baeten et al. found increased CD68+
macrophages in tumor biopsy samples of rectal cancer patients
after radiotherapy and Kioi et al. demonstrated an increase in
CD11b+ myeloid cells in glioblastomas recurring after radiation
(Baeten et al., 2006; Kioi et al., 2010).
Ahn et al. demonstrated that radiation treatment of MT1A2
mouse mammary tumors results in an influx of CD11b+ cells
expressing high levels in MMP-9 in either irradiated tumors or
tumors grown in a pre-irradiated tumor bed (Ahn and Brown,
2008). Additionally, the expression of MMP-9 by CD11b+
myelomonocytes was necessary for vascular restoration and
tumor growth in irradiated tissues. Finally, selective depletion
of CD11b+ cells by a monoclonal antibody inhibited tumor
growth in pre-irradiated tissues (Ahn et al., 2010). Taken together,
these data demonstrate that TAMs promote tumor growth and
stimulates early tumor regrowth through improved blood vessel
formation.
The influx of TAMs after radiation appears to be the result
of increased levels of the transcription factor HIF-1, secondary
to increased tumor hypoxia after irradiation. Using an dual
inhibitor of both HIF-1 and HIF-2, Kioi et al. found a decrease
in the number of radiation-induced BMDC infiltration (mostly
CD11b+ cells) in an orthotopic mouse xenograft model of
human glioblastoma (Kioi et al., 2010). Similarly, treatment of
mice with irradiated tumors using carrageenan, to deplete sys-
temic monocytes/macrophages, also resulted in decreased tumor
infiltration of CD11b+ cells after radiation treatment. Further,
ionizing radiation induced elevated levels of the downstream
HIF-1 target, SDF-1, within U251 tumor xenografts. Blocking
the interaction of SDF-1 and its receptor CXCR4, by using the
CXCR4 inhibitor AMD3100 or a CXCR4 neutralizing antibody,
resulted in decreased tumor perfusion and an enhanced radiore-
sponse of the glioma xenograft model. Interestingly, Kozin et al.
also showed an increase in CD11b+ myeloid cells in irradiated
tumors and demonstrated that whole body radiation (deplet-
ing the bone marrow compartment) combined with the local
irradiation of a tumor site resulted in improved local tumor
control compared to local radiation alone (Kozin et al., 2010).
Additionally, an infusion of myeloid progenitor cells improved
tumor regrowth after local radiation. Similar to the study by
Kioi et al. SDF-1 was also found to be upregulated in irradi-
ated tumor tissues and blocking the SDF-1/CXCR4 interaction
with AMD3100 inhibited tumor re-growth after radiation. Both
studies found that Tie2+ BMDCs were significantly increased
in tumors after local radiation and that these cells, while local-
ized to the vasculature, were not incorporated into tumor vessel
walls.
Chiang et al. found that CD68+ TAMs accumulate in hypoxic
regions of certain tumors, but this is dependent on the tumor
type as well as the local microenvironment (Chiang et al., 2012).
However, after radiation therapy, CD11b+myeloid cells were dis-
tributed into distinct spatial locations: CD68+ TAMs were found
in areas of central hypoxia, while F4/80+ TAMs were found on
the edge of hypoxic regions adjacent to necrotic regions. They
proposed that radiation therapy may activate specific factors to
localize or retain CD68+ TAMs into anoxic or hypoxic regions.
Finally, they determined that the radiation-activated CD68+
TAMs expressed Arg I, indicating a polarization toward the M2
phenotype ofmacrophage, and that TAM recruitment was depen-
dent on SDF-1. An additional study has indicated that tumors
implanted into pre-irradiated fields grow slower than in unirradi-
ated control tissues (i.e., the “tumor bed effect”) and demonstrate
an aggregation of CD68+ TAMs in hypoxic regions (Chen et al.,
2011). Furthermore, when BMDCs were injected systemically
into mice with tumors grown in a pre-irradiated field, they incor-
porated specifically into the tumor vasculature of the low blood
vessel density regions.
In addition to the SDF-1/CXCR4 pathway enhanced by
radiation-induced tumor hypoxia, the CSF-1/CSF1R signal-
ing complex has also been recently implicated in recruitment
of myeloid cells to growing tumors and in promoting the
radiation-induced monocytic infiltration of tumors. Dorsch et al.
demonstrated that transfection of the human CSF-1 gene into a
synergetic mouse model resulted in increased TAM infiltration
of the tumor (Dorsch et al., 1993). Another study determined
that the CSF-1 ligand could stimulate monocytes to produce
VEGF and form microtubule structures in vitro (Eubank et al.,
2003). Using a small molecule inhibitor to the receptor of CSF-1,
Priceman et al. found that the CSF-1/CSF1R pathway was neces-
sary for the recruitment of TAMs, promoted tumor progression,
and the release of proangiogenic cytokines (Priceman et al., 2010).
www.frontiersin.org July 2013 | Volume 4 | Article 157 | 5
Russell and Brown Vascular recovery in irradiated microenvironments
Recently, Xu et al. demonstrated that radiation increased TAM
accumulation in tumors, upregulated in vivo tumor expres-
sion of CSF-1 and interestingly, in irradiated prostate cancer
patients, found that serum levels of CSF-1 were also increased
(Xu et al., 2013). A selective inhibitor of the CSF-1 recep-
tor combined with radiation therapy suppressed tumor growth
compared to radiation alone. They proposed that the mech-
anism for the increased CSF-1 expression in tumors was by
radiation-induced DNA damage resulting in the activation and
translocation of the ABL kinase into the cell nucleus, binding to
the CSF-1 gene promoter, and the enhancement of CSF-1 gene
transcription.
CONCLUSIONS
Following tumor irradiation, DNA damage, cell death, and
increased tumor hypoxia promotes the production of VEGF,
SDF-1, and CSF-1 resulting in the recruitment, infiltration,
and retention of monocytes/macrophages within tumors. The
recruited heterogeneous populations of TAMs release proangio-
genic cytokines and metalloproteinases to promote blood ves-
sel formation within tumors. The level of hypoxia appears to
distribute particular TAM subgroups to specific regions of the
tumor. While the TEM subset is frequently localized to the
perivascular niche, other subpopulations of TAMs are divided
across necrotic, peri-necrotic, and low oxygen tension regions.
Additionally, M2 macrophage polarization appears to be the
dominant phenotype within hypoxic tumors.
Radiation is a unique therapy modality as it causes DNA dam-
age and enhances tumor hypoxia, but only within a targeted
region. Radiation-induced recruitment of TAMs appears to occur
in a similar manner as that caused by tumor hypoxia, is par-
tially dependent on the SDF-1/CXCR4 and CSF-1/CSFR signaling
pathways, and promotes polarization toward the M2 phenotype.
Thus, the accumulation of radiation-induced TAMs within a
tumor may result in the increased production of proangiogenic
cytokines, the recovery of the vascular network, and consequently,
tumor regrowth.
While the generalized process of TAM recruitment has been
identified, many unanswered questions and challenges remain.
First, the heterogeneous population of TAMs needs to be clearly
identified both by phenotypic markers and function. Which
markers clearly define the subpopulations of TAMs? Are the
radiation-induced TAM populations different from the tumor
resident TAMs? Furthermore, does TAM infiltration of irradi-
ated tumors change over time (i.e., an acute response and/or a
chronic response)? What are the functions of the specific TAM
subgroups (i.e., cytokine release, extracellular matrix remodel-
ing, or immunosuppression)? Second, several cytokine-related
signaling pathways have been implicated in the recruitment of
TAMs to irradiated tumor sites; however, much more research
is needed. For example, what are the specific intracellular and
extracellular signaling pathways driving TAM recruitment and
distribution within a tumor? And, does radiation merely enhance
hypoxic signaling or does it generate its own unique signaling
network? Thus, the radiation-induced signaling pathways driv-
ing TAM recruitment, distribution, and function remain to be
fully elucidated. Thirdly, retrospective clinical data suggests that
increased macrophage infiltration of tumors is often a poor prog-
nostic feature. Could the subtype of TAM infiltration into tumors
be used as a more specific prognostic tool? Would it be possible
to stratify patients based on the subtype of TAM infiltration (pre
or post-radiation) to certain risk groups or even select for certain
treatment strategies? Additional studies are needed to correlate
clinical outcomes with the biological data in order to answer these
questions.
Finally, evidence supports that TAMs promote tumor growth
and survival. By understanding which TAM subsets are most
beneficial to the tumor and by defining the intra- and extra-
cellular pathways, novel therapies can be developed to disrupt
TAM recruitment and function. Therefore, ablation of TAM infil-
tration within tumors may be a unique strategy to enhance the
effectiveness of radiation therapy by decreasing angiogenic signal-
ing, disrupting vascular recovery, reducing local tumor recurrence
rates, and decreasing the risk of invasion and metastasis.
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